Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:NVO NYSE:OGE NASDAQ:OMER NASDAQ:QURE NASDAQ:SDST On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNVONovo Nordisk A/S$53.24-0.3%$56.51$45.05▼$115.26$237.70B0.6812.06 million shs9.31 million shsOGEOGE Energy$46.19-0.6%$45.17$39.10▼$47.33$9.30B0.591.13 million shs859,576 shsOMEROmeros$7.65-1.2%$4.80$2.95▼$13.60$520.66M2.321.63 million shs1.34 million shsQUREuniQure$59.33-1.0%$33.65$5.35▼$65.14$3.26B0.561.99 million shs988,423 shsSDSTStardust Power$4.77+5.5%$3.79$1.42▼$79.80$40.35M0.18435,909 shs220,289 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNVONovo Nordisk A/S-2.56%-5.90%-12.08%-24.55%-54.17%OGEOGE Energy-0.45%-1.26%+4.76%+3.25%+13.99%OMEROmeros-1.65%-25.72%+80.00%+115.60%+82.55%QUREuniQure-5.01%-4.65%+333.19%+293.89%+800.90%SDSTStardust Power-3.21%-25.90%+67.41%-17.67%-93.88%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNVONovo Nordisk A/S$53.24-0.3%$56.51$45.05▼$115.26$237.70B0.6812.06 million shs9.31 million shsOGEOGE Energy$46.19-0.6%$45.17$39.10▼$47.33$9.30B0.591.13 million shs859,576 shsOMEROmeros$7.65-1.2%$4.80$2.95▼$13.60$520.66M2.321.63 million shs1.34 million shsQUREuniQure$59.33-1.0%$33.65$5.35▼$65.14$3.26B0.561.99 million shs988,423 shsSDSTStardust Power$4.77+5.5%$3.79$1.42▼$79.80$40.35M0.18435,909 shs220,289 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNVONovo Nordisk A/S-2.56%-5.90%-12.08%-24.55%-54.17%OGEOGE Energy-0.45%-1.26%+4.76%+3.25%+13.99%OMEROmeros-1.65%-25.72%+80.00%+115.60%+82.55%QUREuniQure-5.01%-4.65%+333.19%+293.89%+800.90%SDSTStardust Power-3.21%-25.90%+67.41%-17.67%-93.88%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNVONovo Nordisk A/S 2.50Moderate Buy$76.0042.66% UpsideOGEOGE Energy 2.63Moderate Buy$49.005.63% UpsideOMEROmeros 2.75Moderate Buy$27.50259.24% UpsideQUREuniQure 2.83Moderate Buy$71.7521.50% UpsideSDSTStardust Power 2.83Moderate Buy$51.131,017.73% UpsideCurrent Analyst Ratings BreakdownLatest QURE, NVO, OGE, OMER, and SDST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/22/2025OGEOGE EnergyJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$52.00 ➝ $55.0010/21/2025OGEOGE EnergyBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$47.00 ➝ $51.0010/15/2025OMEROmerosNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold10/15/2025OMEROmerosHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $20.0010/15/2025OMEROmerosWBB SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingStrong-Buy$45.0010/15/2025OMEROmerosD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$36.0010/14/2025NVONovo Nordisk A/SBMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Perform$50.00 ➝ $55.0010/14/2025NVONovo Nordisk A/SWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/10/2025OGEOGE EnergyUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$46.00 ➝ $47.0010/8/2025OGEOGE EnergyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy (B)10/8/2025OMEROmerosWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNVONovo Nordisk A/S$42.12B5.65$3.79 per share14.04$4.66 per share11.43OGEOGE Energy$2.99B3.13$4.85 per share9.56$23.09 per share2.01OMEROmerosN/AN/AN/AN/A($3.15) per shareN/AQUREuniQure$27.12M119.48N/AN/A($0.14) per share-421.81SDSTStardust PowerN/AN/AN/AN/A($3.67) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNVONovo Nordisk A/S$14.64B$3.6414.6311.432.4935.60%78.64%24.51%11/5/2025 (Estimated)OGEOGE Energy$441.50M$2.4418.9919.173.2415.27%10.60%3.55%10/29/2025 (Estimated)OMEROmeros-$156.82M-$2.11N/AN/AN/AN/AN/A-55.49%11/12/2025 (Estimated)QUREuniQure-$239.56M-$3.92N/AN/AN/A-1,387.98%-1,010.74%-33.27%11/4/2025 (Estimated)SDSTStardust Power-$23.75M-$5.60N/AN/AN/AN/AN/A-268.49%11/12/2025 (Estimated)Latest QURE, NVO, OGE, OMER, and SDST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/12/2025Q3 2025OMEROmeros-$0.58N/AN/AN/AN/AN/A11/12/2025Q3 2025SDSTStardust Power-$0.30N/AN/AN/AN/AN/A11/5/2025Q3 2025NVONovo Nordisk A/S$0.90N/AN/AN/A$11.98 billionN/A11/4/2025Q3 2025QUREuniQure-$0.87N/AN/AN/A$4.46 millionN/A10/29/2025Q3 2025OGEOGE Energy$1.20N/AN/AN/A$1.04 billionN/A8/14/2025Q2 2025OMEROmeros-$0.55-$0.53+$0.02-$0.43$0.31 million$28.60 million8/13/2025Q2 2025SDSTStardust Power-$0.30-$0.60-$0.30-$0.06N/AN/A8/6/2025Q2 2025 NVONovo Nordisk A/S$0.93$0.97+$0.04$0.91$77.51 billion$11.69 billion7/29/2025Q2 2025OGEOGE Energy$0.58$0.53-$0.05N/A$719.97 million$741.60 million7/29/2025Q2 2025QUREuniQure-$0.89-$0.69+$0.20-$0.69$5.00 million$5.26 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNVONovo Nordisk A/S$0.821.54%N/A22.53%N/AOGEOGE Energy$1.703.66%N/A69.67%18 YearsOMEROmerosN/AN/AN/AN/AN/AQUREuniQureN/AN/AN/AN/AN/ASDSTStardust PowerN/AN/AN/AN/AN/ALatest QURE, NVO, OGE, OMER, and SDST DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date9/23/2025OGEOGE Energyquarterly$0.42503.68%10/6/202510/6/202510/31/20258/6/2025NVONovo Nordisk A/Ssemi-annual$0.41192.4%8/18/20258/18/20258/26/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNVONovo Nordisk A/S0.520.780.56OGEOGE Energy1.160.780.48OMEROmerosN/A0.810.81QUREuniQure1.539.989.98SDSTStardust PowerN/A0.250.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNVONovo Nordisk A/S11.54%OGEOGE Energy71.84%OMEROmeros48.79%QUREuniQure78.83%SDSTStardust Power32.79%Insider OwnershipCompanyInsider OwnershipNVONovo Nordisk A/S0.07%OGEOGE Energy0.55%OMEROmeros12.90%QUREuniQure4.79%SDSTStardust Power55.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNVONovo Nordisk A/S77,3494.47 billion4.46 billionOptionableOGEOGE Energy2,291201.40 million200.29 millionOptionableOMEROmeros21068.06 million59.28 millionOptionableQUREuniQure50054.87 million52.24 millionOptionableSDSTStardust PowerN/A8.46 million3.78 millionN/AQURE, NVO, OGE, OMER, and SDST HeadlinesRecent News About These CompaniesBreakout Momentum Plays You Need to Know About (SDST)...October 23 at 8:16 AM | marketbeat.comStardust Power Inc. Signs Letter of Intent with Prairie Lithium for 6,000 Metric Tons of Lithium Carbonate SupplyOctober 21 at 7:51 AM | quiverquant.comQStardust Power Secures Strategic North American Lithium Supply with Prairie LithiumOctober 21 at 7:30 AM | globenewswire.comStardust Power Inc trading halted, volatility trading pauseOctober 14, 2025 | msn.comStardust Power appoints Ken Pitts as construction, subcontracts directorOctober 14, 2025 | msn.comStardust Power Inc. Appoints Kenneth Pitts as Construction and Subcontracts Director for Muskogee Lithium Refinery ProjectOctober 13, 2025 | quiverquant.comQStardust Power Strengthens Construction Team with Ken PittsOctober 13, 2025 | globenewswire.comStardust Power, New to The Street enter media partnershipOctober 8, 2025 | msn.comNew to The Street Announces 12-Month National Media Partnership with Stardust Power (NASDAQ: SDST)October 7, 2025 | kansascity.comKStardust Power Faces Nasdaq Delisting NoticeOctober 3, 2025 | tipranks.comStardust Power (NASDAQ:SDST) CFO Sells $10,294.20 in StockSeptember 17, 2025 | insidertrades.comStardust Power price target lowered to $11 from $14 at Roth CapitalSeptember 10, 2025 | msn.comStardust Power completes FEL 3 report for Oklahoma lithium refinerySeptember 9, 2025 | msn.comStardust Descends on Battery LaunchSeptember 9, 2025 | baystreet.caStardust Power Completes Key Study for Lithium FacilitySeptember 9, 2025 | tipranks.comStardust Power Inc. Completes FEL 3 Report, Advances Towards Major Lithium Refinery Construction in OklahomaSeptember 9, 2025 | quiverquant.comQStardust Power Completes Front End Loading 3 Report (FEL 3) for Its Oklahoma Lithium RefinerySeptember 9, 2025 | globenewswire.comStardust Power Inc trading halted, news pendingSeptember 6, 2025 | msn.comStardust Power Inc. Approves 1-for-10 Reverse Stock Split to Enhance Compliance with Nasdaq Listing RequirementsSeptember 4, 2025 | quiverquant.comQStardust Power Announces Reverse Stock Split to Regain Nasdaq Compliance and Position for Long-Term GrowthSeptember 4, 2025 | globenewswire.comStardust Power price target lowered to $1.40 from $1.70 at Roth CapitalAugust 20, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines2 AI Stocks With Record Breaking Rallies: Can They Continue?By Dan Schmidt | September 29, 2025AST SpaceMobile's Big Win: Shares Soar on New Deal With VerizonBy Leo Miller | October 11, 2025QURE: Why Analysts See Up to 63% Upside After 250% Single-Day PopBy Leo Miller | October 3, 2025Amazon Is on the Cusp of Becoming a Grocery DisruptorBy Jordan Chussler | October 14, 2025Novo Nordisk’s Akero Therapeutics Buy Targets Eli Lilly’s LeadBy Chris Markoch | October 15, 2025QURE, NVO, OGE, OMER, and SDST Company DescriptionsNovo Nordisk A/S NYSE:NVO$53.24 -0.14 (-0.27%) Closing price 03:59 PM EasternExtended Trading$53.29 +0.05 (+0.10%) As of 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.OGE Energy NYSE:OGE$46.18 -0.27 (-0.57%) Closing price 03:59 PM EasternExtended Trading$46.18 -0.01 (-0.02%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OGE Energy Corp., together with its subsidiaries, operates as an energy services provider in the United States. The company generates, transmits, distributes, and sells electric energy. In addition, it provides retail electric service to approximately 896,000 customers, which covers a service area of approximately 30,000 square miles in Oklahoma and western Arkansas; and owns and operates coal-fired, natural gas-fired, wind-powered, and solar-powered generating assets. OGE Energy Corp. was founded in 1902 and is headquartered in Oklahoma City, Oklahoma.Omeros NASDAQ:OMER$7.65 -0.09 (-1.16%) Closing price 04:00 PM EasternExtended Trading$7.70 +0.05 (+0.65%) As of 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.uniQure NASDAQ:QURE$59.33 -0.58 (-0.97%) Closing price 04:00 PM EasternExtended Trading$59.32 -0.01 (-0.02%) As of 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.Stardust Power NASDAQ:SDST$4.77 +0.25 (+5.53%) Closing price 04:00 PM EasternExtended Trading$4.82 +0.06 (+1.15%) As of 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Stardust Power Inc. is a vertically-integrated lithium refinery that engages in producing battery-grade lithium. The company was founded in 2022 and is based in Greenwich, Connecticut. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Is Oracle’s AI Rally Over? Wall Street Thinks ORCL Could Hit $400 GM Posts Largest Gain Since the Pandemic: Shares Still Look Cheap 3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
